/

Home/Models/MASH (Diet-Induced)

MASH (Diet-Induced)

dietinflammationliver

Species

Mouse

Duration

Protocol ID

M-cG9zdDoyMjc=

Model Overview

Models metabolic dysfunction-associated steatohepatitis (MASH) using high-fat, high-cholesterol diet.

Methodology

Key Endpoints

NAS score
Hepatic triglycerides
ALT/AST levels

Relevant Publications

Maternal Dyslipidaemia Aggravates Offspring Metabolic Dysfunction-Associated Steatotic Liver Disease.

Pedersen K, Buhl SF, Højgaard-Jensen C et al.

Basic Clin Pharmacol Toxicol2026 Jun

THEMIS attenuates MASH by suppressing disease-associated hepatocyte induction and hepatocyte senescence in mice.

Qiu X, Lu Y, Tang Y et al.

J Clin Invest2026 May 1

F-53B exposure accelerates progression from preexisting fatty liver to non-alcoholic steatohepatitis and hepatic fibrosis.

Hu C, Wu L, Zhang Z et al.

iScience2026 May 15

Heme oxygenase-1 induction by hemin: a novel approach to enhance mitochondrial turnover and mitigate diet-induced liver damage.

Wiszniewski M, Caldareri LJ, Mori D et al.

J Physiol Biochem2026 Apr 30

A thioacrylamide-based compound directly counteracts hepatic fibrosis with profound anti-obesity action.

Rohbeck E, Niersmann C, Dewidar B et al.

JHEP Rep2026 Feb 20

View more on PubMed

Related Drugs

Resmetirom (Rezdiffra)

Approved

resmetirom

Wegovy

Approved (MASH - FDA 2025)

Semaglutide

Zepbound

Phase 3

Tirzepatide

Survodutide

Phase 3

Survodutide

Efruxifermin

Phase 3

Efruxifermin

Lanifibranor

Phase 3

Lanifibranor

Pegozafermin

Phase 3

Pegozafermin

Denifanstat

Phase 3

Denifanstat

Retatrutide

Phase 3

Retatrutide

Pemvidutide

Phase 2b

Pemvidutide

Orforglipron

Phase 3

Orforglipron

VK2809

Phase 2b

VK2809